2-Amino-4-chloro-6-methoxypyrimidine

We are 2-Amino-4-chloro-6-methoxypyrimidine CAS: 5734-64-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 5734-64-5
Product Name: 2-Amino-4-chloro-6-methoxypyrimidine
Other Name:
2-Amino-4-chloro-6-methoxypyrimidine
4-Chloro-6-methoxypyrimidin-2-amine
4-methoxy-6-chloro-2-aminopyrimidine
4-chloro-6-methoxypyrimidine-2-ylamine
2-amino-4-methoxy-6-chloropyrimidine
4-Chloro-6-methoxy-2-pyrimidinamine
2-Amino-6-chloro-4-methoxypyrimidine
 
Density: 1.4±0.1 g/cm3
Boiling Point: 349.4±45.0 °C at 760 mmHg
Melting Point: 168-171 °C(lit.)
Molecular Formula: C5H6ClN3O
Molecular Weight: 159.574
Flash Point: 165.1±28.7 °C
Exact Mass: 159.019943
PSA: 61.03000
LogP: 1.64
Vapour Pressure: 0.0±0.8 mmHg at 25°C
Index of Refraction: 1.585
 
Specification
Appearance: White powder
Assay(HPLC): ≥99.0%
Water: ≤0.5%
 
Application
Intermediates of Chlorimuron-Ethyl CAS: 90982-32-4.
Be used as pesticide intermediate, mainly used in the synthesis of the herbicide Chlorimuron-Ethyl.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

2-Amino-4-chloro-6-methoxypyrimidine


Related News: Domestic API companies cooperate with major international companies through commissioned processing, patent transfer, and joint venture production.2,6-Difluorophenol CAS:28177-48-2 The first is the API – which is the central ingredient.2- (7-metoxinaftalen-1-il) etanamina CAS:138113-09-4 Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.Éter etílico del ácido 1-ciclopropil-6,7-difluoro-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxílico CAS:112811-71-9 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.

Related Products
Product Name
3-Chloro-6-(trifluoromethyl)pyridazine View Details
4-(4-Bromo-3-formylphenoxy)benzonitrile View Details
Acetoxyacetyl chloride View Details
Linaclotide manufacturer 3-bromo-9-naphthalen-2-ylcarbazole manufacturer 1,1-Dichloropinacoline manufacturer 2,6-dimethylpyridin-3-amine manufacturer 1,2,3,4-Tetrafluorobenzene manufacturer